Leerink Partnrs Lowers Earnings Estimates for Bio-Techne

Bio-Techne Corp (NASDAQ:TECH) – Leerink Partnrs cut their Q3 2026 EPS estimates for shares of Bio-Techne in a research report issued on Thursday, July 17th. Leerink Partnrs analyst P. Souda now forecasts that the biotechnology company will post earnings per share of $0.52 for the quarter, down from their previous estimate of $0.54. The consensus estimate for Bio-Techne’s current full-year earnings is $1.67 per share.

Several other brokerages have also recently issued reports on TECH. Wells Fargo & Company initiated coverage on Bio-Techne in a research note on Friday, May 30th. They issued an “overweight” rating and a $59.00 price objective on the stock. UBS Group cut their target price on shares of Bio-Techne from $95.00 to $70.00 and set a “buy” rating on the stock in a research report on Friday, May 9th. Wall Street Zen downgraded shares of Bio-Techne from a “buy” rating to a “hold” rating in a research report on Sunday, June 8th. Stifel Nicolaus cut their target price on shares of Bio-Techne from $75.00 to $60.00 and set a “hold” rating on the stock in a research report on Thursday, May 8th. Finally, Royal Bank Of Canada cut their target price on shares of Bio-Techne from $72.00 to $63.00 and set a “sector perform” rating on the stock in a research report on Thursday, May 8th. Seven analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, Bio-Techne has a consensus rating of “Hold” and an average price target of $70.00.

Bio-Techne Trading Down 2.4%

TECH stock opened at $52.02 on Friday. The company has a market capitalization of $8.16 billion, a PE ratio of 63.44, a P/E/G ratio of 2.53 and a beta of 1.39. Bio-Techne has a 12 month low of $46.01 and a 12 month high of $83.62. The firm’s 50-day moving average is $50.52 and its 200 day moving average is $58.32. The company has a debt-to-equity ratio of 0.16, a current ratio of 3.71 and a quick ratio of 2.58.

Bio-Techne (NASDAQ:TECH) last released its earnings results on Wednesday, May 7th. The biotechnology company reported $0.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.51 by $0.05. The firm had revenue of $316.18 million during the quarter, compared to analyst estimates of $317.92 million. Bio-Techne had a net margin of 10.89% and a return on equity of 13.17%. The business’s revenue was up 4.2% on a year-over-year basis. During the same quarter last year, the business earned $0.48 EPS.

Institutional Trading of Bio-Techne

A number of hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. lifted its stake in Bio-Techne by 1.5% in the fourth quarter. Vanguard Group Inc. now owns 18,594,608 shares of the biotechnology company’s stock valued at $1,339,370,000 after buying an additional 275,644 shares during the last quarter. Price T Rowe Associates Inc. MD raised its stake in shares of Bio-Techne by 6.8% during the first quarter. Price T Rowe Associates Inc. MD now owns 11,375,279 shares of the biotechnology company’s stock valued at $666,933,000 after purchasing an additional 721,012 shares in the last quarter. Select Equity Group L.P. raised its stake in shares of Bio-Techne by 129.8% during the first quarter. Select Equity Group L.P. now owns 5,366,003 shares of the biotechnology company’s stock valued at $314,609,000 after purchasing an additional 3,030,644 shares in the last quarter. Ameriprise Financial Inc. raised its stake in shares of Bio-Techne by 7.2% during the fourth quarter. Ameriprise Financial Inc. now owns 4,702,942 shares of the biotechnology company’s stock valued at $338,756,000 after purchasing an additional 317,349 shares in the last quarter. Finally, Invesco Ltd. raised its stake in shares of Bio-Techne by 9.7% during the first quarter. Invesco Ltd. now owns 4,190,115 shares of the biotechnology company’s stock valued at $245,666,000 after purchasing an additional 369,651 shares in the last quarter. Institutional investors and hedge funds own 98.95% of the company’s stock.

Bio-Techne announced that its Board of Directors has authorized a share repurchase plan on Wednesday, May 7th that authorizes the company to buyback $500.00 million in outstanding shares. This buyback authorization authorizes the biotechnology company to purchase up to 6.5% of its stock through open market purchases. Stock buyback plans are typically an indication that the company’s leadership believes its shares are undervalued.

Bio-Techne Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, May 30th. Shareholders of record on Monday, May 19th were given a $0.08 dividend. This represents a $0.32 annualized dividend and a yield of 0.62%. The ex-dividend date was Monday, May 19th. Bio-Techne’s dividend payout ratio (DPR) is 39.02%.

Bio-Techne Company Profile

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.